Related Experiment Videos
Tumor-associated trypsin inhibitor (TATI) and renal function
G Tramonti1, M Ferdeghini, C Donadio
1Unità de Nefrologia, Università di Pisa, Italy.
Kidney International. Supplement
|February 7, 1998
Summary
Tumor-associated trypsin inhibitor (TATI) is a sensitive marker for declining kidney function. Reduced glomerular filtration rate significantly increases serum TATI levels, indicating kidney handling of this tumor marker.
Area of Science:
- Nephrology
- Oncology
- Biochemistry
Background:
- Tumor-associated trypsin inhibitor (TATI) is a low molecular weight protein used as a tumor marker.
- The kidney's role in clearing TATI and its potential as a marker for renal function decline is not fully understood.
Purpose of the Study:
- To investigate the relationship between serum TATI levels and glomerular filtration rate (GFR).
- To compare TATI's renal handling with other markers like beta 2-microglobulin and creatinine.
- To determine TATI's urine excretion and renal extraction rates.
Main Methods:
- Correlational analysis of serum TATI, beta 2-microglobulin, and creatinine with GFR.
- Measurement of urine TATI excretion and renal extraction percentages.
- Statistical analysis using non-parametric Mann-Whitney test.
Main Results:
- Decreased GFR correlated with increased serum levels of TATI, beta 2-microglobulin, and creatinine.
- Serum TATI showed a significant 12.4-fold increase in patients with severe renal failure (GFR < 20 ml/min).
- TATI excretion increased with renal failure, and renal extraction averaged 24.87%.
Conclusions:
- The kidney plays a role in the clearance of TATI.
- Serum TATI is a sensitive indicator of reduced renal function, even in mild to moderate GFR decline.
- TATI emerges as a potential biomarker for monitoring kidney function.